The continuous glucose monitoring (CGM) market in North America has witnessed remarkable growth over the past decade, driven by the increasing prevalence of diabetes, advancements in CGM technology, and rising awareness regarding diabetes management. CGM systems offer a real-time, continuous tracking of glucose levels, providing valuable data for patients with diabetes to manage their condition more effectively. These systems consist of sensors, transmitters, and receivers that work together to monitor glucose levels in real-time, providing a comprehensive and user-friendly method for managing blood glucose fluctuations. As the demand for more advanced diabetes management solutions continues to rise, the North American CGM market is expected to grow significantly.

Market Overview

The North American continuous glucose monitoring (CGM) market plays a critical role in the management of diabetes, one of the most prevalent chronic diseases worldwide. CGM devices allow patients to track glucose levels throughout the day, reducing the need for frequent finger-stick tests and providing more accurate data. With the rising incidence of diabetes and a growing awareness of the benefits of CGM technology, the market is witnessing substantial growth. Key drivers include advancements in CGM technology, increased adoption by healthcare providers, and a rising number of individuals living with diabetes. As the diabetes epidemic continues to grow, the demand for CGM devices in North America is expected to rise, contributing to the expansion of the market.

Market Size and Share

As of 2024, the North American continuous glucose monitoring market was valued at approximately USD 6.1 billion. The market is projected to grow at a robust compound annual growth rate (CAGR) of 16.3% during the forecast period from 2025 to 2034. By 2034, the market value is expected to reach USD 20.3 billion. The U.S. dominates the market, accounting for the largest share due to the high prevalence of diabetes, the increasing adoption of advanced healthcare technologies, and the presence of key industry players. Canada is also witnessing growth in CGM adoption, though at a slightly slower pace compared to the U.S.

Get a free sample request: https://www.expertmarketresearch.com/reports/north-america-continuous-glucose-monitoring-market/requestsample

Market Trends

Technological Advancements in CGM Devices

Recent technological advancements have significantly improved the performance and usability of CGM devices. The latest CGM systems feature improved sensors that provide more accurate readings with greater precision, reducing errors in blood glucose readings. Moreover, some newer systems can be integrated with mobile apps, allowing users to track glucose levels remotely, providing convenience and real-time insights. With continuous improvements in sensor accuracy and ease of use, CGM technology is expected to become more accessible and user-friendly, driving market adoption.

Integration with Insulin Pumps

A growing trend in the CGM market is the integration of CGM devices with insulin pumps, enabling more seamless management of diabetes. By combining CGM technology with insulin delivery systems, patients can benefit from a more automated diabetes management solution, where insulin dosage is adjusted automatically based on real-time glucose data. This integration helps improve glycemic control while reducing the need for frequent manual intervention, which is likely to drive the adoption of both insulin pumps and CGM systems in the North American market.

Rising Awareness and Adoption of Diabetes Management Tools

Increased awareness about the importance of diabetes management tools is contributing to the growing adoption of CGM devices. Educational initiatives by healthcare providers, diabetes organizations, and governments have emphasized the importance of continuous monitoring of glucose levels for effective disease management. As awareness about diabetes prevention and management continues to grow, more people are opting for CGM systems to gain better control over their glucose levels, propelling the market growth.

Shift Toward Home Healthcare

The shift toward home healthcare is another driving force for the continuous glucose monitoring market in North America. With the rise of telemedicine and remote monitoring, many patients now prefer managing their diabetes from the comfort of their homes. CGM devices are ideal for home healthcare applications as they provide real-time data that can be accessed remotely by both patients and healthcare providers. The increased reliance on home-based management of chronic diseases like diabetes is driving the growth of the CGM market in North America.

Market Analysis

Components of CGM Devices

The North American CGM market is primarily driven by the key components of the devices, including sensors, transmitters, and receivers. Sensors are the heart of CGM systems, continuously measuring glucose levels in the interstitial fluid. Transmitters send the data collected by the sensors to receivers or mobile devices. Receivers display glucose readings and can be integrated with mobile apps for tracking and monitoring. Advancements in these components, particularly in sensor technology, are improving the overall performance and accuracy of CGM devices.

Application Segmentation

The CGM market in North America is segmented based on applications, primarily including Type 1 diabetes, Type 2 diabetes, and other applications. Type 1 diabetes, which requires constant glucose monitoring due to its nature, accounts for a significant portion of the market. However, as the prevalence of Type 2 diabetes increases, the demand for CGM devices for this segment is also on the rise. Other applications, such as gestational diabetes and pre-diabetes, are also contributing to the market growth, although to a lesser extent.

Age Group Segmentation

The CGM market is segmented based on age groups, including adult and child populations. Adults, especially those with Type 1 diabetes, constitute the majority of CGM device users. However, the adoption of CGM systems in pediatric populations is also growing, driven by the increasing incidence of Type 1 diabetes in children and the recognition of the benefits of early and continuous glucose monitoring. Pediatric CGM devices are designed to meet the specific needs of younger patients, providing parents and caregivers with better control over their children’s glucose levels.

End User Segmentation

The key end users of CGM devices in North America include hospitals and clinics, home healthcare settings, and others. Hospitals and clinics are significant users of CGM devices, particularly in the management of hospitalized diabetic patients. However, home healthcare is becoming the fastest-growing segment as more patients choose to manage their diabetes independently with remote monitoring solutions. The growing popularity of home healthcare solutions and remote monitoring of chronic diseases, including diabetes, is contributing to the rapid growth of the CGM market in North America.

Regional Insights

United States

The United States is the largest market for continuous glucose monitoring devices in North America, accounting for the majority of market share. The high prevalence of diabetes, coupled with increased healthcare spending and technological advancements, has led to a robust market for CGM systems. In addition, the presence of leading CGM manufacturers and the growing number of people diagnosed with diabetes further contribute to the market’s expansion. The regulatory environment in the U.S. is favorable for the adoption of CGM devices, as the FDA has approved several CGM systems for both adult and pediatric patients.

Canada

While Canada represents a smaller portion of the North American CGM market, the country is experiencing steady growth in the adoption of CGM systems. The Canadian government’s initiatives to improve healthcare access and the growing awareness of diabetes management tools are driving the demand for CGM devices. Additionally, advancements in medical technology and increasing patient preferences for personalized and remote healthcare solutions are contributing to the growth of the CGM market in Canada.

Market Growth

The North American continuous glucose monitoring market is poised for significant growth, driven by the rising prevalence of diabetes, advancements in CGM technology, and increasing consumer awareness. The demand for real-time, continuous glucose monitoring is expected to continue growing as more people seek more effective ways to manage their diabetes. Furthermore, the integration of CGM systems with insulin pumps, the shift towards home healthcare, and the development of age-specific CGM devices are all expected to fuel market expansion in the coming years. The market also stands to benefit from innovations in CGM sensors, transmitters, and receivers, which continue to improve the performance and affordability of these devices.

Recent Developments & Challenges

  • FDA Approval of New CGM Systems: In 2023, the FDA approved several new CGM devices with improved sensor accuracy and longer wear times, further boosting the adoption of these technologies.
  • Integration with Wearables: CGM manufacturers are integrating their devices with wearable technologies such as smartwatches, allowing users to track their glucose levels in real time with more convenience.
  • Reimbursement Challenges: Although the demand for CGM devices is increasing, reimbursement policies for these devices can vary, posing challenges for some patients in accessing affordable devices.
  • Technological Innovations: Companies like Abbott and Dexcom are constantly improving the design and functionality of CGM systems, with next-generation devices offering more accurate readings and enhanced user experience.

Key Players

Abbott

Abbott is one of the leading companies in the North American CGM market, with its popular FreeStyle Libre system. The FreeStyle Libre is known for its ease of use, affordability, and high accuracy, making it a favorite among Type 1 and Type 2 diabetes patients. Abbott continues to innovate, working on expanding its portfolio of CGM devices to meet the diverse needs of diabetic patients.

Dexcom, Inc.

Dexcom is another prominent player in the CGM market, known for its Dexcom G6 and G7 systems. The company offers state-of-the-art CGM systems with integrated mobile apps, providing real-time glucose data and alarms for patients. Dexcom is focusing on making its CGM devices more accessible through partnerships with healthcare providers and insurers.

Medtronic PLC

Medtronic is a global leader in medical technologies and a significant player in the CGM market. The company’s Guardian Connect CGM system offers continuous glucose monitoring for patients with Type 1 and Type 2 diabetes. Medtronic is working to enhance the integration of CGM systems with insulin pumps to provide a more holistic diabetes management solution.

Senseonics, Inc.

Senseonics is known for its innovative Eversense CGM system, which features a long-term implantable sensor that can last up to 180 days. This unique feature differentiates Senseonics from other players in the market, making it an attractive option for patients seeking long-term glucose monitoring solutions.

Other companies involved in the North American CGM market include Byram Healthcare Centers, Inc., Hoffmann-La Roche Limited, and more.

FAQs

Q: What is continuous glucose monitoring (CGM)? CGM is a system used to monitor glucose levels continuously throughout the day. It consists of sensors, transmitters, and receivers to track glucose fluctuations in real time.

Q: How does a CGM system work? A CGM system works by using a small sensor inserted under the skin to measure glucose levels in the interstitial fluid. The data is transmitted to a receiver or smartphone app for monitoring.

Q: Who can benefit from CGM devices? CGM devices are primarily used by individuals with Type 1 or Type 2 diabetes, but they are also beneficial for people with gestational diabetes or prediabetes.

Q: Are CGM devices covered by insurance? Coverage for CGM devices varies by insurance plan. However, many insurers are increasingly covering CGM devices due to their proven benefits in diabetes management.